BioAlliance’s second quarter results bolstered by FDA approval

Tuesday 10 August 2010

BioAlliance Pharma SA posted record revenue of €15.2 million in the 2010 second quarter in what was an illustration of how the fortunes of a small European company can be transformed by a single regulatory approval in the US.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France